Avricore Health Inc. (AVCR.V)
| Previous Close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.1500 x 0 |
| Ask | 0.1550 x 0 |
| Day's Range | 0.1500 - 0.1600 |
| 52 Week Range | 0.1050 - 0.3000 |
| Volume | |
| Avg. Volume | 31,035 |
| Market Cap | 15.445M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Avricore Health Full Year 2023 Earnings: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)
Avricore Health ( CVE:AVCR ) Full Year 2023 Results Key Financial Results Revenue: CA$3.49m (up 97% from FY 2022). Net...
GlobeNewswireAvricore Health Corporate Update and Audited Results for 2023
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce its audited results for 2023. The Company nearly doubled its previous record revenues to $3,485,147 while gross profit increased by 163% to $1,203,396. The Company is currently in an early scale-up and growth period, and therefore has made substantial capital investments with on-hand cash during this period, and yet strong gross margins have allowed t
- GlobeNewswire
HealthTab™ Signs Agreement for More Rexall® Pharmacy Locations
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce further expansion of HealthTab™ with Rexall Pharmacy Group ULC (“Rexall”). The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform. “To successfully screen and manage chronic and infectious disea
